CIRM awards $1.3M to Greenstone Bio for stem cell research involving iPSC-derived cardiovascular cells accelerated by artificial intelligence and machine learning.
Palo Alto, CA, Oct 04, 2022 – Greenstone Biosciences, Inc. (“Greenstone Bio”), a commercial-stage computational biology company, announces that the Company has received a DISC0 grant funding from the California Institute of Regenerative Medicine (CIRM).
Greenstone Bio (Stanford Research Park) focuses on clinical genomics, human induced pluripotent stem cell (iPSC) technology, artificial intelligence / machine learning (AI/ML), and drug development. The Company has extensive knowledge and expertise in generating patient-derived iPSCs. The Company currently possesses the largest patient-derived iPSC Biobank and offering cell lines to academic collaborators at no cost.
This CIRM grant will allow Greenstone Bio to perform pre-clinical studies on genetic cardiovascular diseases. Greenstone Bio’s investigators will use AI/ML approaches to drug screening and drug discovery. Furthermore, Greenstone Bio will validate compounds for safety and efficacy using iPSC-derived cardiovascular cells from disease and healthy patients to fast-track drug discovery.
By supplementing preclinical data obtained from animal models with data from disease-relevant human cell lines derived from patients of diverse backgrounds, Greenstone Bio will establish an evaluation process for preclinical studies that predicts clinical trial outcomes while investigating the influence of genetic backgrounds on drug candidates (i.e., pharmacogenomics and personalized medicine).
This will facilitate predicting the safety and efficacy of drugs, stratify patient populations, and determine potential severe adverse events. Greenstone Bio believes these approaches can help accelerate drug discovery and de-risk clinical trials by establishing a “clinical trial in a dish” platform.
Dr. Joseph Wu, Greenstone Bio co-founder, said, “This is a great collaboration that translates Greenstone Bio’s expertise in clinical genomics, iPSC, and AI/ML technology to accelerate therapies to improve patient care.” Dr. Wu is the Director of the Stanford Cardiovascular Institute and the Simon H. Stertzer, MD, Professor of Medicine & Radiology at Stanford University. Greenstone Bio Board Chairman Lip-Bu Tan of Walden Catalyst Venture is a long-term strategic partner. Mr. Tan considers this award as a “validation of the strategy that Greenstone Bio is undertaking that will lead to faster bench to bedside translation.”
About Greenstone Biosciences, Inc.
Greenstone Bio is a commercial-stage computational biology company specializing in stem cell technology, artificial intelligence & machine learning, and drug discovery. For further information, visit www.greenstonebio.com.
To learn more about the rapidly expanding market for iPSCs, view the “Global Induced Pluripotent Stem Cell (iPS Cell) Industry Report 2022.”
